Head-to-head

CJC-1295 vs MOTS-c

A field-by-field comparison of CJC-1295 and MOTS-c drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. They belong to different categories — growth hormone and metabolic — so this page focuses on what each one actually does rather than which is "better".

CJC-1295 vs MOTS-c at a glance

Attribute	CJC-1295	MOTS-c
Category	Growth hormone	Metabolic
Evidence grade	Moderate	Emerging
Also known as	Modified GRF 1-29, DAC:GRF	Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1-encoded peptide
Chain	30 amino acid GHRH analogue	16 amino acid mitochondrial-derived peptide
Mechanism	Binds pituitary GHRH receptors to increase both the amplitude of GH pulses and total GH secretion. The DAC (drug affinity complex) version binds serum albumin, extending the half-life from minutes to about a week.	Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress.
Reported benefits	Elevated GH and IGF-1 across the dosing window · Improved sleep depth reported by most users · Supports lean mass retention and fat oxidation	Improved insulin sensitivity and glucose disposal in rodent models · Enhanced fat oxidation and reduced fat accumulation · Exercise-mimetic effects on metabolism and physical capacity · Potential protection against diet-induced metabolic dysfunction
Reported side effects	Water retention · Tingling or numbness in hands · Head rush and flushing after injection · Elevated fasting glucose at higher doses	Limited human safety data · Injection-site irritation · Possible hypoglycaemia in susceptible individuals
Half-life	~30 minutes without DAC; ~6–8 days with DAC	Estimated minutes to a few hours
Administration	Subcutaneous injection, typically before bed on an empty stomach	Subcutaneous injection; oral capsules are marketed but less validated
Dosing overview	100 mcg (no-DAC) 1–3× daily, or 1–2 mg weekly for the DAC version	Commonly cited at 5–10 mg daily, often for 4–12 week cycles
Storage	Refrigerate reconstituted product; protect from light and avoid shaking	Lyophilised powder refrigerated; reconstituted vials 2–8 °C and used within ~30 days
Legal status	Not FDA-approved. Prescribed off-label by some clinics; banned in sport.	Research chemical; not approved as a drug.

Key differences between CJC-1295 and MOTS-c

Different categories, different goals

CJC-1295 is indexed under growth hormone, while MOTS-c sits under metabolic. They are not substitutes for one another: CJC-1295 is described as "A growth-hormone-releasing hormone analogue that raises the baseline of natural GH output rather than replacing it." and MOTS-c as "A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects."

Mechanism of action

CJC-1295: Binds pituitary GHRH receptors to increase both the amplitude of GH pulses and total GH secretion. The DAC (drug affinity complex) version binds serum albumin, extending the half-life from minutes to about a week. MOTS-c: Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress.

Evidence quality is not equal

CJC-1295 carries a Moderate evidence grade and MOTS-c a Emerging grade on this index. The grade describes the quality of published human data, not how well a compound works — CJC-1295 has the better-documented record of the two, and claims made about MOTS-c rest on thinner human evidence.

Half-life and dosing frequency

CJC-1295 is listed at ~30 minutes without dac; ~6–8 days with dac; MOTS-c at estimated minutes to a few hours. That difference is what drives the reported schedules: 100 mcg (no-DAC) 1–3× daily, or 1–2 mg weekly for the DAC version versus Commonly cited at 5–10 mg daily, often for 4–12 week cycles

Route of administration

CJC-1295 is administered by subcutaneous injection, typically before bed on an empty stomach. MOTS-c is administered by subcutaneous injection; oral capsules are marketed but less validated.

Legal and regulatory status differs

CJC-1295: Not FDA-approved. Prescribed off-label by some clinics; banned in sport. MOTS-c: Research chemical; not approved as a drug. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.

Handling and storage

CJC-1295 is stored refrigerate reconstituted product; protect from light and avoid shaking. MOTS-c is stored lyophilised powder refrigerated; reconstituted vials 2–8 °c and used within ~30 days.

What CJC-1295 and MOTS-c have in common

On the attributes tracked in this database — category, evidence grade, mechanism, half-life, administration, dosing overview, storage and legal status — CJC-1295 and MOTS-c share no identical values. They are compared here because they come up together in the same searches, not because they overlap.

Each compound in brief

CJC-1295

Growth hormone · Moderate evidence

A growth-hormone-releasing hormone analogue that raises the baseline of natural GH output rather than replacing it.

Considerations: Usually paired with a GHRP such as Ipamorelin for a synergistic pulse · No-DAC (Mod GRF 1-29) suits pulsatile dosing; DAC suits steady elevation · GH elevation is not desirable for everyone — screen for cancer history

MOTS-c

Metabolic · Emerging evidence

A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects.

Considerations: Most evidence is preclinical; human trials are small and early-phase · Short half-life may require daily or twice-daily dosing · Bioavailability of oral forms is uncertain compared with injection